
Opinion|Videos|July 2, 2024
cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
Tarita O. Thomas, MD, PhD discusses patients with LS-SCLC, and what she would consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor. The panel also discusses the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC.
Advertisement
Episodes in this series

- In patients with LS-SCLC, what would you consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor?
- Please discuss your thoughts on the range of time prior to initiating therapy - from immediately to 6 weeks post-cCRT.
- What is the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC?
- What is the role of SBRT in earlier stages of disease vs cCRT followed by durvalumab?
Advertisement
Related to this article

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

